Table 2.
Best candidates selected by PLS-DA for triage and prognosis of radiation-induced skin burns.
| Best protein candidates based on PLS-DA | |||||||
|---|---|---|---|---|---|---|---|
| Protein name | Accession (Uniprot KB) |
Name in DB | Spot number 1 | Irradiation 2,3 | Dose 2,4 | ||
| Max fold change (p < 0.05) |
p-value | Max fold change (p < 0.05) |
p-value | ||||
| Apolipoprotein A-I | APOA1_MOUSE | APOA1 | 1335 | = | / | −1.3 | 6.0 10−4 |
| Apolipoprotein E | APOE_MOUSE | APOE | 1099 | −1.2 | 1.0 10−2 | = | / |
| Apolipoprotein H | APOH_MOUSE | APOH | 626 | +1.2 | 4.4 10−3 | +1.2 | 8.2 10−3 |
| Coagulation factor X | FA10_MOUSE | F10 | 778 | −1.2 | 2.2 10−3 | = | / |
| Complement C1r-A subcomponent | C1RA_MOUSE | C1R | 475 | = | / | +1.3 | 6.3 10−5 |
| Complement component 7 | CO7_HUMAN | C7 | 400, 401 | −1.3 | 2.5 10−4 | = | / |
| Complement factor H | CFAH_MOUSE | CFH | 164 | +1.1 | 4.5 10−3 | = | / |
| Complement factor I | CFAI_MOUSE | CFI | 1057 | −1.1 | 1.5 10−3 | +1.2 | 2.0 10−3 |
| Fetuin B | FETUB_MOUSE | FETUB | 676 | +1.2 | 1.7 10−5 | +1.1 | 2.4 10−3 |
| Murinoglobulin 1 | MUG1_MOUSE | Mug1 | 627 | +1.1 | 2.5 10−2 | +1.1 | 2.8 10−3 |
| Pantothenate kinase 4 | PANK4_MOUSE | PANK4 | 1129 | +1.9 | 2.9 10−11 | +1.6 | 3.6 10−7 |
| Peroxiredoxin-2 | PRDX2_MOUSE | PRDX2 | 1413 | = | - | −1.3 | 1.6 10−2 |
| Plasminogen | PLMN_MOUSE | PLG | 309 | −1.2 | 1.1 10−3 | −1.3 | 4.2 10−3 |
| Serine protease inhibitor A3K | SPA3K_MOUSE | Serpina3k | 1671 | −1.6 | 2.0 10−3 | −1.3 | 4.0 10−2 |
| Non-identified | - | - | 1599 | +1.7 | 1.8 10−3 | = | / |
1 Spot numbers assigned by Progenesis SameSpots software according to their position in 2-DE gels; 2 Max Fold Changes associated with a p-value < 0.05. Fold changes and results of statistical tests (p- and q-values, Power) are comprehensively given in Supplemental Table S3; 3 Max fold changes are given for irradiated samples compared to controls (sham-irradiated) samples; 4 Max fold changes are given for comparisons of irradiated samples (20, 40 and 80 Gy) (the highest dose versus the lowest dose).